Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained before any assessment is performed.~2. Physician diagnosis of asthma, as per GINA guidelines GINA guidelines and currently prescribed ICS or ICS-LABA therapy.~3. Patients who are demonstrated to have reversible airway obstruction, significant FEV1 variability or airway hyperresponsiveness (AHR), or who have shown such responses in previous test(s) within the last five years.~4. An ACQ score ≥ 1.5 at randomization or ≥ 1 exacerbations (requiring higher than the patient's normal dose of OCS or IV corticosteroids for ≥ 3 days) in the past 12 months. The definition of exacerbations includes episodes during which the patient self-administered higher doses of OCS as part of a documented self-management plan initiated by the patient's general practitioner or respiratory physician.~5. Patients currently on GINA step 2 to step 5 asthma therapies.~6. Sputum eosinophil count ≥ 2% at screening.~Exclusion Criteria:~1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.~2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (CRTH2 antagonists).~3. History of long QT syndrome or whose QTc interval (Fridericia's) is prolonged \>450 msec for males and \>470 msec for females at screening or baseline.~4. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~5. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/mL).~6. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during the study treatment and for 5 days (5 half-lives) after treatment.~7. Acute illness other than asthma which, in the investigator's opinion, may compromise the well-being of the patient or study endpoint assessments at the start of the study~8. Patients who are considered unsuitable for inclusion by the assessing physician due to serious co-morbidities such as cancer, emphysema or significant bronchiectasis.~9. Recent (within 6 weeks of screening) or current lower respiratory tract infection.~10. Patients who have been hospitalized or required high-dose (\>10mg prednisolone/day) oral corticosteroid (OCS) therapy within 6 weeks of the screening visit.~11. Patients with clinically significant laboratory abnormalities (not associated with the study indication) at screening.~12. Patients who have a clinically significant abnormality on a 12-lead ECG recorded within one month prior to or at screening.~13. Patients with a body mass index (BMI) \< 17 or \> 40 kg/m2.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QAW039 (Type: EXPERIMENTAL): Eligible patients will receive QAW039 po 450 mg daily dose.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to QAW039 (oral capsules) will be administered to match QAW039 schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).